WONDERS-2: Once-Weekly Oral HIV-1 Therapy Trial Discontinued
Gilead Sciences has halted Phase 2/3 trials of its investigational once-weekly oral HIV therapy, WONDERS-2, following an eight-month FDA clinical hold. This regulatory pause prioritizes patient safety over speed, addressing ... Read More